At the end of the inspection, no 'Form 483' was issued.

Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.

The company's consolidated net profit declined 13.5% to Rs 454.71 crore despite of 16.1% rise in net sales to Rs 3,040.91 crore in Q3 FY23 over Q3 FY22.

The scrip had shed 0.45% to end at Rs 3392.75 on the BSE.